 | |
| Clinical data | |
|---|---|
| Trade names | Parabolan, Hexabolan |
| Other names | Trenbolone cyclohexylmethylcarbonate; Estra-4,9,11-trien-17β-ol-3-one 17β-cyclohexylmethylcarbonate |
| Routes of administration | Intramuscular |
| Drug class | Androgen;Anabolic steroid;Androgen ester;Progestogen |
| Legal status | |
| Legal status | |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard(EPA) | |
| ECHA InfoCard | 100.041.503 |
| Chemical and physical data | |
| Formula | C26H34O4 |
| Molar mass | 410.554 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Trenbolone hexahydrobenzylcarbonate, ortrenbolone cyclohexylmethylcarbonate, sold under the brand namesParabolan andHexabolan, is asynthetic,injectedanabolic–androgenic steroid (AAS) of thenandrolone group and anandrogen ester – specifically, the C17β hexahydrobenzylcarbonate (cyclohexylmethylcarbonate)ester oftrenbolone – which was marketed inFrance for medical use in humans but has since been discontinued.[1]
It was introduced in France in 1980 and was voluntarily discontinued by its manufacturer in 1997.[1][2] The drug acts as a long-lastingprodrug of trenbolone when administered viaintramuscular injection.[1] It was used clinically at a dosage of oneampoule (76 mg, corresponding to 50 mg trenbolone base) every 10 days.[1]
 | Thisdrug article relating to thegenito-urinary system is astub. You can help Wikipedia byexpanding it. |
 | Thisdrug article relating to thegastrointestinal system is astub. You can help Wikipedia byexpanding it. |